Research programme: cancer immunotherapies - TESARO/M.D. Anderson Cancer Center
Latest Information Update: 31 Mar 2016
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer TESARO; University of Texas M. D. Anderson Cancer Center
- Class Small molecules
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 29 Mar 2016 Early research in Cancer in USA (unspecified route)